Evidence map›Paper›PMID 34430715›Full record

ArticleBiochemistry and biophysics reports2021

Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia.

Hidemasa Matsuo, Kana Nakatani, Yutarou Harata, Moe Higashitani, Yuri Ito, Aina Inagami, Mina Noura, Tatsutoshi Nakahata, Souichi Adachi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hidemasa MatsuoHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kana NakataniHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yutarou HarataHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Moe HigashitaniHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuri ItoHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Aina InagamiHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Mina NouraHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsutoshi NakahataDrug Discovery Technology Development Office, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Souichi AdachiHuman Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most frequent cytogenetic abnormalities in acute myeloid leukemia (AML) is t(8;21). Although patients with t(8;21) AML have a more favorable prognosis than other cytogenetic subgroups, relapse is still common and novel therapeutic approaches are needed. A recent study showed that t(8;21) AML is characterized by

Indexed as

ApoptosisAutophagyCDK4/6Leukemiat(8;21)

Identifiers

PMID34430715
PMCPMC8371187

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.